Huron price target raised to $165 from $140 at Benchmark

Benchmark raised the firm’s price target on Huron (HURN) to $165 from $140 and keeps a Buy rating on the shares following the company’s “strong” Q4 report and 2025 guidance. The macro set up is “increasingly compelling,” particularly in healthcare, with the potential emergence of changes in clinical reimbursement models, reduced NIH funding levels for research and stricter eligibility for Medicaid patients, the analyst tells investors.